News

Find News

Filter articles

Applied Filters

Showing 811 to 820 of 910 results

Cephalon launches another Treanda action

01-05-2014

Cephalon has filed another lawsuit to protect its chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma treatment Treanda (bendamustine hydrochloride), this time against Canadian pharmaceutical company Uman Pharma.

Actavis and Pfizer settle Celebrex litigation

US29-04-2014Legal developments

Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Federal Circuit rules against Roche in Tamiflu case

India, US25-04-2014Legal developments

The US Court of Appeals for the Federal Circuit has thrown out a lower court ruling that found Natco Pharma infringed a patent covering Roche’s flu drug Tamiflu (oseltamivir phosphate).

Depomed settles with generics over Gralise dispute

US16-04-2014Legal developments

Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.

Generics file Teva response in Copaxone battle

US15-04-2014

A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

UK High Court strikes down Herceptin patents

UK14-04-2014Legal developments

The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.

Purdue sues Teva to block OxyContin challenge

US08-04-2014

OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification.

Teva asks US Supreme Court to stay ruling in Copaxone case

US08-04-2014Legal developments

Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

Sun Pharma to acquire rival Ranbaxy for $3.2bn

India07-04-2014Mergers & acquisitions

Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed.

Eli Lilly drafts in Prasco to market Evista generic

US03-04-2014

Generic drug maker Prasco Laboratories has agreed to market and distribute an authorised generic version of Eli Lilly’s Evista (raloxifene hydrochloride) in the US.

Showing 811 to 820 of 910 results

LSIPR